Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model

Abstract excerpt

Neovascular age-related macular degeneration (nAMD) is a frequent cause of vision loss among the elderly in the Western world. Current disease management with repeated injections of anti-VEGF agents accumulates the risk for adverse events and constitutes a burden for society and the individual patient. Sustained suppression of VEGF using gene therapy is an attractive alternative, which we explored using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Retinal Development and Disorders
• Share to Retinal Diseases and Treatments
• Share to RNA Interference and Gene Delivery